A month after I blogged about Fosamax, the NY Times has run a front page story on the horrible dilemma facing patients with cancer or osteoporosis. The FDA has now required bisphosphonate labels to disclose the serious side effects of death of areas of bone in the jaw, which may occur in one of 10 patients who take the drug. Pharmaceutical companies are defending about 20 suits filed so far by denying that osteonecrosis occurred in their clinical trials. This is scary stuff.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.